Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

Cited by (1,002)

Items 101–200 of 1,002

1. Biological Role and Therapeutic Potential of IDH Mutations in Cancer
   Matthew S. Waitkus, Bill H. Diplas, Hai Yan · 2018 · Cancer Cell
2. Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma
   Zeju Li, Yuanyuan Wang, Jinhua Yu, Yi Guo, Wei Cao · 2017 · Scientific Reports
3. R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis
   Ying Qing, Lei Dong, Lei Gao, Chenying Li, Yangchan Li, Li Han, Emily A. Prince, Brandon Tan, Xiaolan Deng, Collin Wetzel et al. · 2021 · Molecular Cell
4. Integrated genomic characterization of IDH1-mutant glioma malignant progression
   Hanwen Bai, Akdes Serin Harmancı, Zeynep Erson-Omay, Jie Li, Süleyman Coşkun, Matthias Simon, Boris Krischek, Koray Özduman, Sacit Bulent Omay, Eric A. Sorensen et al. · 2015 · Nature Genetics
5. Unified One-Step Multi-View Spectral Clustering
   Chang Tang, Zhenglai Li, Jun Wang, Xinwang Liu, Wei Zhang, En Zhu · 2022 · IEEE Transactions on Knowledge and Data Engineering
6. Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
   Ingo K. Mellinghoff, Benjamin M. Ellingson, Mehdi Touat, Elizabeth Anne Maher, Macarena I. de la Fuente, Matthias Holdhoff, Gregory Michael Cote, Howard A. Burris, Filip Jankú, Robert J. Young et al. · 2020 · Journal of Clinical Oncology
7. Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer
   Petralia, Francesca, Tignor, Nicole, Reva, Boris, Koptyra, Mateusz, Chowdhury, Shrabanti, Rykunov, Dmitry, Krek, Azra, Ma, Weiping, Zhu, Yuankun, Ji, Jiayi et al. · 2020 · Cell
8. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
   Philipp Kickingereder, Felix Sahm, Alexander Radbruch, Wolfgang Wick, Sabine Heiland, Andreas von Deimling, Martin Bendszus, Benedikt Wiestler · 2015 · Scientific Reports
9. Tissue mechanics regulate brain development, homeostasis and disease
   James Matthew Barnes, Laralynne Przybyla, Valerie M. Weaver · 2017 · Journal of Cell Science
10. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours
    Horbinski, Craig, Berger, Tamar, Packer, Roger J., Wen, Patrick Y. · 2022 · Nature Reviews Neurology
11. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma
    Damian Stichel, Azadeh Ebrahimi, David Reuß, Daniel Schrimpf, Takahiro Ono, Mitsuaki Shirahata, Guido Reifenberger, Michael Weller, Daniel Hänggi, Wolfgang Wick et al. · 2018 · Acta Neuropathologica
12. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas
    Aoki, Kosuke, Nakamura, Hideo, Suzuki, Hiromichi, Matsuo, Keitaro, Kataoka, Keisuke, Shimamura, Teppei, Motomura, Kazuya, Ohka, Fumiharu, Shiina, Satoshi, Yamamoto, Takashi et al. · 2018 · Neuro-Oncology
13. Machine Learning–Based Radiomics for Molecular Subtyping of Gliomas
    Chia‐Feng Lu, Fei‐Ting Hsu, Kevin Li‐Chun Hsieh, Yu‐Chieh Jill Kao, Sho‐Jen Cheng, Justin Bo‐Kai Hsu, Ping‐Huei Tsai, Ray‐Jade Chen, Chao Huang, Yun Yen et al. · 2018 · Clinical Cancer Research
14. Understanding TERT Promoter Mutations: A Common Path to Immortality
    Robert J.A. Bell, H. Tomas Rube, Ana Xavier‐Magalhães, Bruno Marques Costa, Andrew Mancini, Jun S. Song, J Costello · 2016 · Molecular Cancer Research
15. Surgical resection versus watchful waiting in low-grade gliomas
    Asgeir Store Jakola, Anne Jarstein Skjulsvik, Kristin Smistad Myrmel, Kristin Sjåvik, Geirmund Unsgård, SVERRE HELGE TORP, Kirsten Aaberg, T. Berg, H.Y. Dai, Kay-Martin Johnsen et al. · 2017 · Annals of Oncology
16. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications
    Tathiane Maistro Malta, Camila Ferreira de Souza, Thaís S. Sabedot, Tiago C. Silva, Maritza S. Mosella, Steven N. Kalkanis, James Snyder, Ana Valeria B. Castro, Houtan Noushmehr · 2017 · Neuro-Oncology
17. Recurrent and functional regulatory mutations in breast cancer
    Esther Rheinbay, Prasanna Parasuraman, Jonna Grimsby, Grace Tiao, J Engreitz, Jaegil Kim, Michael S. Lawrence, Amaro N Taylor-Weiner, Sergio Arturo Rodriguez-Cuevas, Mara W. Rosenberg et al. · 2017 · Nature
18. Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response
    Sabine Hombach‐Klonisch, Maryam Mehrpour, Shahla Shojaei, Craig Henry Harlos, Marshall W. Pitz, Ahmed Hamaï, Krzysztof Siemianowicz, Wirginia Likus, Emilia Wiecheć, Brian D. Toyota et al. · 2017 · Pharmacology & Therapeutics
19. Glioma: experimental models and reality
    Krissie Lenting, Roel G.W. Verhaak, Mark ter Laan, Pieter Wesseling, William P. J. Leenders · 2017 · Acta Neuropathologica
20. Progress in glioma diagnosis, classification and treatment
    Patrick Yung Wen, David A. Reardon · 2016 · Nature Reviews Neurology
21. Characteristics of H3 K27M-mutant gliomas in adults
    David Meyronet, Maud Esteban-Mader, Charlotte Bonnet, Marie‐Odile Joly, Emmanuelle Uro‐Coste, Alexandra Benouaich‐Amiel, Fabien Forest, Cécilia Rousselot‐Denis, Fanny Burel‐Vandenbos, Veronique Bourg et al. · 2016 · Neuro-Oncology
22. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
    David Reuß, Annekathrin Kratz, Felix Sahm, David Capper, Daniel Schrimpf, Christian Koelsche, Volker Hovestadt, Melanie Bewerunge‐Hudler, David Jones, Jens Schittenhelm et al. · 2015 · Acta Neuropathologica
23. Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
    Ingo K. Mellinghoff, Marta Peñas-Prado, Katherine B. Peters, Howard A. Burris, Elizabeth Anne Maher, Filip Jankú, Gregory Michael Cote, Macarena Ines de la Fuente, Jennifer Leigh Clarke, Benjamin M. Ellingson et al. · 2021 · Clinical Cancer Research
24. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma
    Carl Johannes Koschmann, Anda‐Alexandra Calinescu, Felipe Javier Núñez, Alan G. Mackay, Janet Fazal-Salom, Daniel Thomas, Flor Mendez, Neha Kamran, Marta Dzaman, Lakshman Mulpuri et al. · 2016 · Science Translational Medicine
25. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas
    Romain Appay, Caroline Dehais, Claude‐Alain Maurage, Agustí Alentorn, Catherine Carpentier, Carole Colin, François Ducray, Fabienne Escande, Ahmed Idbaïh, Aurélie Kamoun et al. · 2019 · Neuro-Oncology
26. Mutant IDH1 and seizures in patients with glioma
    Hao Chen, Jonathon Judkins, Cheddhi Thomas, Meijing Wu, Laith Khoury, Carolina Benjamin, Donato R. Pacione, John G. Golfinos, Priya Kumthekar, Farhad Ghamsari et al. · 2017 · Neurology
27. Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response
    Philipp Kickingereder, MICHAEL A. GOETZ, John Muschelli, Antje Wick, Ulf Neuberger, Russell Taki Shinohara, Martin Sill, Martha Nowosielski, Heinz-Peter Schlemmer, Alexander Radbruch et al. · 2016 · Clinical Cancer Research
28. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures
    Adrienne Johnson, Eric Allan Severson, Laurie M. Gay, Jo‐Anne Vergilio, Julia Andrea Elvin, James H. Suh, Sugganth Daniel, Mandy Covert, Garrett Michael Frampton, Sigmund H. Hsu et al. · 2017 · The Oncologist
29. Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response
    Kevin C. Johnson, Kevin J. Anderson, Elise T. Courtois, Amit D. Gujar, Floris P Barthel, Frederick S. Varn, Diane Luo, Martine Seignon, Eunhee S. Yi, Hoon Kim et al. · 2021 · Nature Genetics
30. Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells
    Hua Lin, Shaan Patel, Valerie Affleck, Ian Wilson, Douglass M. Turnbull, Abhijit R. Joshi, Ross J. Maxwell, Elizabeth Ann Stoll · 2016 · Neuro-Oncology
31. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response
    Felipe Javier Núñez, Flor Mendez, Padma Kadiyala, Mahmoud S. Alghamri, Masha G. Savelieff, María Belén Garcia-Fabiani, Santiago Haase, Carl Johannes Koschmann, Anda‐Alexandra Calinescu, Neha Kamran et al. · 2019 · Science Translational Medicine
32. Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics
    Yoon Seong Choi, Sohi Bae, Jong Hee Chang, Seok‐Gu Kang, Se Hoon Kim, Jinna Kim, Tyler Hyungtaek Rim, Seung Hong Choi, Rajan Jain, Seung‐Koo Lee · 2020 · Neuro-Oncology
33. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions
    Julie J. Miller, L. Nicolas Gonzalez Castro, Samuel K. McBrayer, Michael Weller, Timothy Francis Cloughesy, Jana Portnow, Ovidiu C. Andronesi, Jill S. Barnholtz‐Sloan, Brigitta G. Baumert, Mitchel Stuart Berger et al. · 2022 · Neuro-Oncology
34. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
    Ingo K. Mellinghoff, Min Lu, Patrick Yung Wen, Jennie Webster Taylor, Elizabeth Anne Maher, Isabel Arrillaga‐Romany, Katherine B. Peters, Benjamin M. Ellingson, Marc K. Rosenblum, Saewon Chun et al. · 2023 · Nature Medicine
35. The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision
    Takashi Komori · 2017 · Neurologia medico-chirurgica
36. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation
    David W. Ellison, Cynthia E Hawkins, David Jones, Arzu Onar‐Thomas, Stefan Michael Pfister, Guido Reifenberger, David N. Louis · 2019 · Acta Neuropathologica
37. Purine metabolism regulates DNA repair and therapy resistance in glioblastoma
    Weihua Zhou, Yangyang Yao, Andrew J. Scott, Kari Wilder-Romans, Joseph Dresser, Christian K. Werner, Hanshi Sun, Drew W. Pratt, Peter Sajjakulnukit, Shuang George Zhao et al. · 2020 · Nature Communications
38. A radiomic signature as a non-invasive predictor of progression-free survival in patients with lower-grade gliomas
    Xing Liu, Yiming Li, Zenghui Qian, Zhiyan Sun, Kaibin Xu, Kai Wang, Shuai Liu, Xing Fan, Shaowu Li, Zhong Zhang et al. · 2018 · NeuroImage Clinical
39. Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates
    Ye, Dan, Guan, Kun-Liang, Xiong, Yue · 2018 · Trends in Cancer
40. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022
    Craig Horbinski, Burt Nabors, Jana Portnow, Joachim M. Baehring, Ankush Bhatia, Orin G. Bloch, Steven S. Brem, Nicholas Arthur Butowski, Donald Maurice Cannon, Samuel T. Chao et al. · 2023 · Journal of the National Comprehensive Cancer Network
41. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
    Farshad Farshidfar, Siyuan Zheng, Marie‐Claude Gingras, Yulia Newton, Juliann Shih, A. Gordon Robertson, Toshinori Hinoue, Katherine A. Hoadley, Ewan A. Gibb, Jason Roszik et al. · 2017 · Cell Reports
42. Predicting clinical outcomes from large scale cancer genomic profiles with deep survival models
    Safoora Yousefi, Fatemeh Amrollahi, Mohamed T. Amgad, Chengliang Dong, Joshua E. Lewis, Congzheng Song, David A. Gutman, Sameer H. Halani, Jose Enrique Velazquez Vega, Daniel Jay Brat et al. · 2017 · Scientific Reports
43. Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
    Danielle Golub, Nishanth S. Iyengar, Siddhant Dogra, Taylor Wong, Devin Bready, Karen Tang, Aram Sandaldjian Modrek, Dimitris G. Placantonakis · 2019 · Frontiers in Oncology
44. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017
    Burt Nabors, Jana Portnow, Mario Ammirati, Joachim M. Baehring, Henry Brem, Nicholas Arthur Butowski, Robert Alan Fenstermaker, Peter A. Forsyth, Jona Ashok Hattangadi-Gluth, Matthias Holdhoff et al. · 2017 · Journal of the National Comprehensive Cancer Network
45. The role of neuropathology in the management of patients with diffuse low grade glioma
    Daniel P. Cahill, Andrew Edward Sloan, Brian Vala Nahed, Kenneth Aldape, David N. Louis, Timothy Charles Ryken, Steven N. Kalkanis, Jeffrey J. Olson · 2015 · Journal of Neuro-Oncology
46. Oligodendroglioma: pathology, molecular mechanisms and markers
    Pieter Wesseling, Martin J. van den Bent, Arie Perry · 2015 · Acta Neuropathologica
47. Predicting Deletion of Chromosomal Arms 1p/19q in Low-Grade Gliomas from MR Images Using Machine Intelligence
    Zeynettin Akkus, Issa M. Ali, Jiří Sedlář, Jay P. Agrawal, Ian F. Parney, Caterina Giannini, Bradley James Erickson · 2017 · Journal of Imaging Informatics in Medicine
48. Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics
    Artemiy Silantyev, Luca Falzone, Massimo Libra, Olga Ivanovna Gurina, K. Sh. Kardashova, Τaxiarchis Κonstantinos Νikolouzakis, Alexander E. Nosyrev, Chris W. Sutton, Panayiotis D. Mitsias, Aristidis Michael Tsatsakis · 2019 · Cells
49. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide
    Wolfgang Wick, Patrick Roth, Christian Johannes Hartmann, Peter Hau, Makoto Nakamura, Florian Stockhammer, Michael Sabel, Antje Wick, Susanne Koeppen, Ralf Ketter et al. · 2016 · Neuro-Oncology
50. The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology
    Daniel N. Cagney, Joohee Sul, Raymond Y. Huang, Keith Lloyd Ligon, Patrick Yung Wen, Brian Michael Alexander · 2017 · Neuro-Oncology
51. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
    de Botton, Stephane, Mondesir, Johanna, Willekens, Christophe, Touat, Mehdi · 2016 · Journal of Blood Medicine
52. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma
    Bell, Erica H., Zhang, Peixin, Shaw, Edward G., Buckner, Jan C., Barger, Geoffrey R., Bullard, Dennis E., Mehta, Minesh P., Gilbert, Mark R., Brown, Paul D., Stelzer, Keith J. et al. · 2020 · Journal of Clinical Oncology
53. Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 32 TCGA cancer types
    Aristeidis G. Telonis, Rogan G. Magee, Phillipe Loher, Inna Chervoneva, Eric R. Londin, Isidore Rigoutsos · 2017 · Nucleic Acids Research
54. Temozolomide-associated hypermutation in gliomas
    Serah Choi, Yao Yu, Matthew Grimmer, Michael Traut Wahl, Susan Marina Chang, J Costello · 2018 · Neuro-Oncology
55. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria
    C. Mircea S. Tesileanu, Linda Dirven, Maarten M.J. Wijnenga, Johan A F Koekkoek, Arnaud J.P.E. Vincent, Hendrikus Jan Dubbink, Peggy N. Atmodimedjo, Johan M. Kros, Sjoerd G. van Duinen, Marion Smits et al. · 2019 · Neuro-Oncology
56. Adult IDH wild-type lower-grade gliomas should be further stratified
    Abudumijit Aibaidula, Aden Ka‐Yin Chan, Zhifeng Shi, Yanxi Li, Ruiqi Zhang, Rui Yang, Kay Ka‐Wai Li, Nellie Yuk‐Fei Chung, Yu Yao, Liangfu Zhou et al. · 2017 · Neuro-Oncology
57. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
    Nimish A. Mohile, Hans J. Messersmith, Na Tosha Gatson, Andreas Felix Hottinger, Andrew B. Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson et al. · 2021 · Journal of Clinical Oncology
58. Multi-Channel 3D Deep Feature Learning for Survival Time Prediction of Brain Tumor Patients Using Multi-Modal Neuroimages
    Nie, Dong, Lu, Junfeng, Zhang, Han, Adeli, Ehsan, Wang, Jun, Yu, Zhengda, Liu, LuYan, Wang, Qian, Wu, Jinsong, Shen, Dinggang · 2019 · Scientific Reports
59. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers
    Étienne Becht, Nicolás A. Giraldo, Claire Germain, Aurélien de Reyniès, Pierre Laurent‐Puig, Jessica Zucman‐Rossi, Marie‐Caroline Dieu‐Nosjean, Catherine Sautès‐Fridman, Wolf H. Fridman · 2016 · Advances in immunology
60. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma
    Jinhua Yu, Zhifeng Shi, Yuxi Lian, Zeju Li, Tongtong Liu, Yuan Gao, Yuanyuan Wang, Liang Chen, Ying Qing Mao · 2016 · European Radiology
61. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study
    Martinus P. G. Broen, Marion Smits, Maarten M.J. Wijnenga, Hendrikus Jan Dubbink, Monique H. M. E. Anten, Olaf E. M. G. Schijns, Jan C. Beckervordersandforth, Alida Annechien Postma, Martin J. van den Bent · 2018 · Neuro-Oncology
62. Multi-omic tumor data reveal diversity of molecular mechanisms that correlate with survival
    Daniele Ramazzotti, Avantika Lal, Bo Wang, Serafim Batzoglou, Arend Sidow · 2018 · Nature Communications
63. Oncometabolites in renal cancer
    Cissy Yong, Grant Duncan Stewart, Christian Frezza · 2019 · Nature Reviews Nephrology
64. The REMBRANDT study, a large collection of genomic data from brain cancer patients
    Yuriy Gusev, Krithika Bhuvaneshwar, Lei Song, Jean-Claude Zenklusen, Howard Alan Fine, Subha Madhavan · 2018 · Scientific Data
65. CD70, a novel target of CAR T-cell therapy for gliomas
    Linchun Jin, Haitao Ge, Yu Long, Changlin Yang, Yifan Emily Chang, Luyan Mu, Elias Joseph Sayour, Gabriel De Leon, Qiong J. Wang, James Chih‐Hsin Yang et al. · 2017 · Neuro-Oncology
66. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review
    Audra N. Boscoe, Catherine Rolland, Robin Kate Kelley · 2019 · Journal of Gastrointestinal Oncology
67. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer
    Owen Clark, Katharine E. Yen, Ingo K. Mellinghoff · 2016 · Clinical Cancer Research
68. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation
    Andrea E. Calvert, Alexandra Chalastanis, Yongfei Wu, Lisa Hurley, Fotini M. Kouri, Yingtao Bi, Maureen T. Kachman, Jasmine May, Elizabeth T. Bartom, Youjia Hua et al. · 2017 · Cell Reports
69. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH -Mutant Glioma
    Choi, Changho, Raisanen, Jack M., Ganji, Sandeep K., Zhang, Song, McNeil, Sarah S., An, Zhongxu, Madan, Akshay, Hatanpaa, Kimmo J., Vemireddy, Vamsidhara, Sheppard, Christie A. et al. · 2016 · Journal of Clinical Oncology
70. The genetic landscape of ganglioglioma
    Melike Pekmezci, Javier E. Villanueva-Meyer, Benjamin Goode, Jessica Van Ziffle, Courtney S. Onodera, James P. Grenert, Boris C. Bastian, Gabriel Chamyan, Ossama M. Maher, Ziad A. Khatib et al. · 2018 · Acta Neuropathologica Communications
71. Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity
    Nobuyuki Tanaka, Shigeaki Kanatani, Raju Tomer, Cecilia Sahlgren, Pauliina Kronqvist, Dagmara Kaczyńska, Lauri M. Louhivuori, Lorand Levente Kis, Claes Lindh, Przemysław Mitura et al. · 2017 · Nature Biomedical Engineering
72. Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing
    Philipp Euskirchen, Franck Bielle, Karim Labrèche, Wigard P. Kloosterman, Shai Rosenberg, Maïlys Daniau, Charlotte Schmitt, Julien Masliah‐Planchon, Franck Bourdeaut, Caroline Dehais et al. · 2017 · Acta Neuropathologica
73. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid
    Francisco Martínez Ricarte, Regina Mayor, Elena A. Martínez-Sáez, Carlota Rubio-Pérez, Estela Pineda, Esteban Cordero, Marta Cicuéndez, Maria Antonia Poca, Núria López-Bigas, Santiago Ramón y Cajal et al. · 2018 · Clinical Cancer Research
74. Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging
    Todd Charles Hollon, Cheng Jiang, Asadur Chowdury, Mustafa Nasir-Moin, Akhil Kondepudi, Alexander A. Aabedi, Arjun Rohit Adapa, Wajd N. Al‐Holou, Jason Heth, Oren Sagher et al. · 2023 · Nature Medicine
75. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma
    Macarena I. de la Fuente, Robert J. Young, Jennifer Rubel, Marc K. Rosenblum, Jamie Tisnado, Samuel R. Briggs, Julio Arevalo Perez, Justin R. Cross, Carl Campos, Kimberly S. Straley et al. · 2015 · Neuro-Oncology
76. Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma
    Shawn L. Hervey‐Jumper, Yalan Zhang, Joanna J. Phillips, Ramin A. Morshed, Jacob S. Young, Lucie S. Mccoy, Marisa Lafontaine, Tracy L. Luks, Simon Gashaw Ammanuel, Sofia Kakaizada et al. · 2023 · Journal of Clinical Oncology
77. The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment
    Henry Rodriguez, Jean Claude Zenklusen, Louis M. Staudt, James H. Doroshow, Douglas R. Lowy · 2021 · Cell
78. G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma
    Wang, Yuxiang, Yang, Jie, Wild, Aaron T., Wu, Wei H., Shah, Rachna, Danussi, Carla, Riggins, Gregory J., Kannan, Kasthuri, Sulman, Erik P., Chan, Timothy A. et al. · 2019 · Nature Communications
79. Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas
    Mark W. Youngblood, Daniel Durán, Julio D. Montejo, Chang Li, Sacit Bulent Omay, Koray Özduman, Amar H. Sheth, Amy Zhao, Evgeniya Tyrtova, Danielle F. Miyagishima et al. · 2019 · Journal of neurosurgery
80. Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma‐Tailored Gene Panel
    Angela Zacher, Kerstin Kaulich, Stefanie Stepanow, Marietta Wolter, Karl Köhrer, Jörg Felsberg, Bastian Malzkorn, Guido Reifenberger · 2016 · Brain Pathology
81. Hallmarks of glioblastoma: a systematic review
    Dorte Schou Nørøxe, Hans Skovgaard Poulsen, Ulrik Lassen · 2016 · ESMO Open
82. Imaging Correlates of Adult Glioma Genotypes
    Marion Smits, Martin J. van den Bent · 2017 · Radiology
83. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium
    Kenneth Aldape, Samirkumar B. Amin, David M. Ashley, Jill S. Barnholtz‐Sloan, Amanda J Bates, Rameen Beroukhim, Christoph Bock, Daniel Jay Brat, Elizabeth B. Claus, J Costello et al. · 2018 · Neuro-Oncology
84. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence
    Camila Ferreira de Souza, Thaís S. Sabedot, Tathiane Maistro Malta, Lindsay C. Stetson, Olena Morozova, Artem Sokolov, Peter W. Laird, Maciej Wiznerowicz, Antonio Iavarone, James Snyder et al. · 2018 · Cell Reports
85. An independently validated survival nomogram for lower-grade glioma
    Haley R Gittleman, Andrew Edward Sloan, Jill S. Barnholtz‐Sloan · 2019 · Neuro-Oncology
86. Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System
    Takashi Komori · 2021 · Laboratory Investigation
87. Mutant IDH1 and thrombosis in gliomas
    Dusten J. Unruh, Steven R. Schwarze, Laith Khoury, Cheddhi Thomas, Meijing Wu, Li Chen, Rui Chen, Yinxing Liu, Margaret A. Schwartz, Christina Amidei et al. · 2016 · Acta Neuropathologica
88. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
    Bill H. Diplas, Xujun He, Jacqueline A. Brosnan‐Cashman, Heng Liu, Lee H. Chen, Zhaohui Wang, Casey J. Moure, Patrick J. Killela, Daniel B. Loriaux, Eric Lipp et al. · 2018 · Nature Communications
89. Immunosuppressive Myeloid Cells’ Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy
    Neha Kamran, Padma Kadiyala, Meghna Saxena, Marianela Candolfi, Youping Li, Mariela A. Moreno-Ayala, Nicholas Saleem Raja, Diana Shah, Pedro Ricardo Lowenstein, Maria Graciela Castro · 2017 · Molecular Therapy
90. Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care
    Ugljesa Djuric, Gelareh Mohammed Zadeh, Kenneth Aldape, Phedias Diamandis · 2017 · npj Precision Oncology
91. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T
    Daniel Paech, Johannes Windschuh, Johanna Oberhollenzer, Constantin Dreher, Felix Sahm, Jan‐Eric Meissner, Steffen Goerke, Patrick Schuenke, Moritz Zaiß, Sebastian Regnery et al. · 2018 · Neuro-Oncology
92. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: A report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial
    Dubbink, Hendrikus J., Atmodimedjo, Peggy N., Kros, Johan M., French, Pim J., Sanson, Marc, Idbaih, Ahmed, Wesseling, Pieter, Enting, Roelien, Spliet, Wim, Tijssen, Cees et al. · 2016 · Neuro-Oncology
93. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma
    Peng Zhang, Jason M. Miska, Catalina Lee-Chang, Aida Rashidi, Wojciech K. Panek, Shejuan An, Μαρκέλλα Ζαννίκου, Aurora Lopez‐Rosas, Yu Han, Ting Xiao et al. · 2019 · Proceedings of the National Academy of Sciences
94. Classification of adult‐type diffuse gliomas: Impact of the World Health Organization 2021 update
    Benjamin T. Whitfield, Jason T. Huse · 2022 · Brain Pathology
95. Myc-Driven glycolysis is a therapeutic target in glioblastoma
    Tateishi, Kensuke, Iafrate, A. John, Ho, Quan, Curry, William T., Batchelor, Tracy T., Flaherty, Keith T., Onozato, Maristela L., Lelic, Nina, Sundaram, Sudhandra, Cahill, Daniel P. et al. · 2016 · Clinical Cancer Research
96. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression
    Xiaoran Zhang, Aparana Rao, Paola Sette, Christopher Deibert, Alexander Pomerantz, Wi Jin Kim, Gary Kohanbash, Yigang Chang, Yongseok Park, Johnathan A. Engh et al. · 2016 · Neuro-Oncology
97. Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas
    Philip Jonsson, Andrew L. Lin, Robert J. Young, Natalie M. DiStefano, David Michael Hyman, Bob T. Li, Michael F. Berger, Ahmet Zehir, Marc Ladanyi, David B. Solit et al. · 2019 · Clinical Cancer Research
98. Prediction ofIDH1-Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas
    Yae Won Park, Kyunghwa Han, Sung Soo Ahn, Sohi Bae, Yoon Seong Choi, Jong Hee Chang, Se Hoon Kim, Seok‐Gu Kang, Seung‐Koo Lee · 2017 · American Journal of Neuroradiology
99. A TGF ‐β signaling‐related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response
    Weiwei Duan, Liting Yang, Jian Liu, Zi‐Yu Dai, Zeyu Wang, Hao Zhang, Xun Zhang, Xisong Liang, Peng Luo, Jian Zhang et al. · 2023 · CNS Neuroscience & Therapeutics
100. Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications
     Julie J. Miller, Helen Alice Shih, Ovidiu C. Andronesi, Daniel P. Cahill · 2017 · Cancer